PI Industries Biologicals Revenue Grew Over 250% in Q2 FY27
Key highlights
- PI reported biologicals revenue growth of more than 250% in Q2 FY27.
- Harpinαβ™ was commercialized in 23 countries and the biologicals platform covered 4.7 million acres globally, excluding India.
- PI expanded its distribution network threefold in Brazil, Mexico and Spain.
- R&D investment increased 102% in H1 FY27 versus H1 FY26, while market and product-development investment rose 108%.
powered by IRIS

PI Industries reported biologicals revenue growth of more than 250% in Q2 FY27, supported by commercial activity across biostimulants, biocontrol and plant-nutrition solutions. PI said its biologicals platform covered 4.7 million acres globally, excluding India, while Harpinαβ™ had been commercialized in 23 countries.
Know P I Industries inside out
Results, valuation, peers and who's buying, in one view.
What drove PI’s biologicals revenue growth in Q2 FY27?
PI reported revenue growth of more than 250% for biologicals in Q2 FY27 as it expanded commercial products, distribution and development outside India. The platform is powered by PREtec™, or Pi Precision Peptides, and spans biostimulants, biocontrol and plant-nutrition solutions. PI did not disclose biologicals revenue in rupees, the comparison-quarter revenue base, or segment profit.
The revenue increase coincided with higher investment in commercial development and research. Market and product-development investment rose 108%, while research and development, or R&D, investment increased 102% in H1 FY27 versus H1 FY26. PI said the R&D spending was intended to strengthen peptide discovery and development, but did not provide programme-level expenditure.
PI’s reported global footprint provides context for the Q2 FY27 growth rate. Harpinαβ™ was commercialized in 23 countries and the platform covered 4.7 million acres globally, excluding India. PI also reported more than 900 field trials involving more than 1,000 growers across Brazil, Mexico, Europe and the US.
Which biological products has PI commercialized globally?
PI has commercialized biostimulant and biocontrol products, including what it describes as the world’s first biological foliar-application nematicide in Mexico and the US. Its biostimulant portfolio includes ProAct Foliar Spray, BioVita, HPlant and Employ. The biocontrol portfolio includes ShaNema, Teikko, PILLIN, Saori and Moshy™.
PI’s product list combines different biological applications rather than relying on a single brand. Harpinαβ™ had been commercialized in 23 countries, while the foliar nematicide had been commercialized specifically in Mexico and the US. The presentation does not disclose sales, acreage or country-by-country performance for ProAct, Teikko, Saori, ShaNema or other individual products.
The 4.7 million-acre measure applies to the biologicals platform globally and excludes India. It is therefore not stated as acreage for Harpinαβ™ alone, the foliar nematicide, or any individual geography. PI’s more than 900 field trials and more than 1,000 growers instead describe product-development activity in Brazil, Mexico, Europe and the US.
Got a follow-up? Ask IRIS
How is PI expanding biologicals distribution and development?
PI expanded its biologicals distribution network threefold in Brazil, Mexico and Spain, while building a US Midwest network. The completed threefold expansion occurred alongside a 108% increase in market and product-development investment. PI did not disclose the number of distributors before or after the expansion in the three markets.
The company paired route-to-market expansion with field development in four regions. More than 900 trials and engagement with more than 1,000 growers were reported across Brazil, Mexico, Europe and the US. PI said this activity was strengthening relationships with key influencers and stakeholders, but did not provide country-level trial or grower numbers.
PI’s 102% increase in R&D investment in H1 FY27 versus H1 FY26 was directed at peptide discovery and development. Its broader R&D platform includes more than 50 projects at different stages, four laboratory locations and more than 700 scientists, including more than 200 doctorates. PI did not state that those wider R&D figures relate solely to biologicals.
The US Midwest network is described as being built, unlike the threefold expansion already reported in Brazil, Mexico and Spain. This distinguishes an ongoing US route-to-market initiative from completed distribution growth in the three other markets. PI did not disclose a timetable, distributor count or revenue target for the Midwest network.
What are PI’s next biologicals launches and label plans?
PI plans to launch five brands in the US and has three peptides state-registered for a 2027 launch. The five named brands are Saori, ProAct, PREdefender, Physera and Atalio. PI did not identify the relevant states, specify launch dates during 2027, or disclose expected sales volumes and revenue.
In Brazil, PI is pursuing label expansions in corn and cotton for Teikko and Saori. The company identified two products and two crops, but did not say whether the label expansions had been approved, submitted or remained under development. In the UK, PI said it had relaunched ProAct.
The US launch plan follows biologicals revenue growth of more than 250% in Q2 FY27 and the 102% H1 FY27 increase in R&D investment. PI’s disclosure links the planned brands to its peptide-led biologicals development and market-building programme. It does not provide a target for US acreage, new distributors, biologicals revenue or the timing of Brazil’s label expansions.
Conclusion
PI’s biologicals business combined revenue growth of more than 250% in Q2 FY27 with a broader international commercial base. The platform reported 4.7 million acres covered globally, excluding India, Harpinαβ™ commercialization in 23 countries, and a threefold distribution expansion across Brazil, Mexico and Spain. Higher market-development and R&D investment indicates that PI is continuing to fund product and market expansion.
The next disclosed milestone is the planned 2027 US launch of five brands supported by three state-registered peptides. Progress on Teikko and Saori label expansions for Brazilian corn and cotton, the build-out of the US Midwest network, and any future disclosure of biologicals revenue or distributor numbers will show how PI’s stated commercial plans develop.


